Co-Diagnostics Faces Delisting Notice

TL;DR

CDXC got a delisting notice, stock might be in trouble.

AI Summary

Co-Diagnostics, Inc. filed an 8-K on January 10, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company, incorporated in Utah, is based in Salt Lake City and operates in the surgical and medical instruments sector.

Why It Matters

This filing indicates potential issues with Co-Diagnostics' continued listing on an exchange, which could impact its stock trading and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading and overall financial health.

Key Numbers

• 1-38148 — SEC File Number (Identifies the company's filing with the SEC)

Key Players & Entities

• Co-Diagnostics, Inc. (company) — Filer of the 8-K report
• January 10, 2025 (date) — Date of the earliest event reported
• Salt Lake City, Utah (location) — Principal executive offices location
• 46-2609363 (dollar_amount) — IRS Employer Identification Number

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share CODX The Nasdaq Capital M
• $1.00 — iness days had closed below the minimum $1.00 per share required for continued listin
• $1 — he Company's common stock must close at $1 or more for a minimum of ten consecutiv

Filing Documents

• form8-k.htm (8-K) — 35KB
• 0001493152-25-001705.txt ( ) — 206KB
• codx-20250110.xsd (EX-101.SCH) — 3KB
• codx-20250110_lab.xml (EX-101.LAB) — 33KB
• codx-20250110_pre.xml (EX-101.PRE) — 24KB
• form8-k_htm.xml (XML) — 4KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2025 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employer incorporation or organization) File Number) Identification Number) 2401 S. Foothill Drive , Suite D , Salt Lake City , Utah 84109 (Address of principal executive offices) (801) 438-1036 (Issuer's telephone number) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share CODX The Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 10, 2025, Co-Diagnostics, Inc. ("CODX" or "the Company") received a notice from Nasdaq Listing Qualifications department (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") stating that the closing bid price of the Company's common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Listing Rule 5550(a)(2). The Company has a period of 180 calendar days, or until July 9, 2025 (the "Compliance Date"), to regain compliance with Listing Rule 5550(a)(2). To regain compliance, the bid price of the Company's common stock must close at $1 or more for a minimum of ten consecutive business days before the Compliance Date. The Nasdaq notification letter does not result in the immediate delisting of the Company's common stock, and the stock will continue to trade uninterrupted on the The Nasdaq Capital Market under the symbol "CODX". If the Company does not regain compliance with Rule 5550(a)(2) by the Compliance Date, the Company may be eligible for additional time. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company meets these requirements, the Staff will inform the Company that it has been granted an additional 180 calendar days. However, if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, the Staff will provide notice that its securities will be subject to delisting. The Company intends to actively monitor the closing bid price for its common stock and will consider available options to resolve the deficiency and regain compliance with Nasdaq Listing Rule 5550(a)(2). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CO-DIAGNOSTICS, INC. Date: January 10, 2025 By: /s/ Brian Brown Name: Brian Brown Title: Chief Financial Officer (Principal Financial and Accounting Officer)

View Full Filing

View this 8-K filing on SEC EDGAR